Companies

Zydus receives USFDA nod for anti-fungal, skin drug

Our Bureau Ahmedabad | Updated on January 13, 2018 Published on February 17, 2017

Cadila Healthcare Ltd (Zydus Cadila) on Friday said it has received final approval from the USFDA to market Fluconazole tablets USP and Clobetasol Propionate spray.

In a statement here, the company said Fluconazole tables, used in the treatment of fungal infections, and manufactured at the Baddi facility, will be sold in the USA in the strengths of 50, 100, 150 and 200 mg.

Clobetasol Propionate spray, used in the treatment of various skin disorders, and manufactured at the Changodar facility, will be sold in the strength of 0.05%.

The Zydus Group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Published on February 17, 2017
This article is closed for comments.
Please Email the Editor